Studying of biofilm formation by clinical strains of Candida albicans in interaction with Fusarium solani to predict the severity of atopic dermatitis

Abstract

Aim. To assess the ability to form biofilms by clinical strains of the yeast Candida albicans isolated from patients with atopic dermatitis in exacerbation and remission stages under the effect of Fusarium solani micromycete and its absence.

Methods. The study included 70 strains of C. albicans and one strain of F. solani. Fungal biofilms formed accor­ding to the method of Ramage. The optical density of the biofilms measured using a micro plate reader at 620 nm. The effect of associated fungi on the biofilm-forming properties of C. albicans strains was studied by an extract from opportunistic F. solani fungi.

Results. The greatest biofilm formation was observed in strains isolated at the remission stage. The strains isolated in the acute period were inferior to them in the ability to form biofilms (average values of film formation were 0.143 and 0.087, respectively). Co-cultivation of C. albicans strains with F. solani fungus extract stimulated biofilm formation of C. albicans strains at a concentration of 1:10.

Conclusion. This study showed a possible synergism between C. albicans and F. solani in polymicrobial skin infections, because the products of the fungus F. solani increase one of the virulence factors of the fungus C. albicans; the possibility to assess of a stimulating effect of associated fungi on the virulence one of an agent of infectious disease process will allow predicting the disease severity.

Keywords

Candida albicans / Fusarium solani / biofilms / atopic dermatitis / symbiosis / microbial associations

References

[1] Gurbanova M.G., Gulordava M.D., Chilina G.A. et al. Clinical peculiarities of atopic dermatitis complicated by skin mycoses. Problemy meditsinskoy mikologii. 2012; 14 (4): 43–46. (In Russ.)

[2] Гурбанова М.Г., Гулордава М.Д., Чилина Г.А. и др. Клинические особенности атопического дерматита, осложнённого микозами кожи. Пробл. мед. микол. 2012; 14 (4): 43–46.

[3] Glatz M., Bosshard P., Schmid-Grendelmeier P. The role of fungi in atopic dermatitis. Immunol. Allergy Clin. North Am. 2017; 37 (1): 63–74. DOI: 10.1016/j.iac.2016.08.012.

[4] Fayzullina E.V., Khismatulina I.M., Lisovskaya S.A., Gordeeva A.M. Mo­dern features of the course of acne: the results of own researches. Problemy meditsinskoy mikologii. 2019; 21 (3): 35–38. (In Russ.)

[5] Файзуллина Е.В., Хисматулина И.М., Лисовская С.А., Гордеева А.М. Современные особенности течения акне: результаты собственных исследований. Пробл. мед. микол. 2019; 21 (3): 35–38.

[6] Golub A.V. Bacterial biofilms — a new therapeutic target? Clinical Microbiology and Antimic­robial Chemotherapy. 2012; 14 (1): 23–29. (In Russ.)

[7] Голуб А.В. Бактериальные биоплёнки — новая цель терапии? Клин. микробиол., антимикробная химиотерап. 2012; 14 (1): 23–29.

[8] Costa-Orlandi C.B., Sardi J.C.O., Pitangui N.S. et al. Fungal biofilms and polymicrobial diseases. J. Fungi (­Basel). 2017; 3 (2): 22. DOI: 10.3390/jof3020022.

[9] Nikitina L.E., Lisovskaya S.А., Startseva V.A. et al. Development of novel effective agents against Candida albicans biofilms. BioNanoScience. 2019; 9: 539–544. DOI: 10.1007/s12668-019-00648-6.

[10] Lisovskaya S.A., Khaldeeva E.V., Glushko N.I., Parshakov V.R. Evaluation of biofilm formation ability of clinical strains of Candida albicans isolated at the acute and chronic forms of candidosis of the skin and mucous membranes. Problemy meditsinskoy mikologii. 2017; 19 (1): 31–33. (In Russ.)

[11] Лисовская С.А., Халдеева Е.В., Глушко Н.И., Паршаков В.Р. Оценка способности к формированию биоплёнок клиническими штаммами Candida albicans, выделенными при острых и хронических формах кандидоза кожи и слизистых оболочек. Пробл. мед. микол. 2017; 19 (1): 31–33.

[12] Federal'nye klinicheskie rekomendatsii. Dermatovenerologiya 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. (Federal clinical guidelines. Dermatovenerology 2015. Diseases of the skin. Sexually transmitted infections.) Ed. 5th ed. M.: Business Express. 2016; 768 p. (In Russ.)

[13] Федеральные клинические рекомендации. Дерматовенерология 2015. Болезни кожи. Инфекции, передаваемые половым путём. Изд. 5-е, испр. и доп. М.: Деловой экспресс. 2016; 768 с.

[14] Klimko N.N. Diagnosis and treatment of candidaemia and acute disse­minated candidiasis. Infektsionnaya i antimikrobnaya tera­piya. 2002; 4 (1): 30–37. (In Russ.)

[15] Климко Н.Н. Диагностика и лечение кандидемии и острого диссеминированного кандидоза. Инфекц. и антимикроб. терап. 2002; 4 (1): 30–37.

[16] Ramage G., Walle K.V., Wickes B.L., Lopez-Ribot J.L. Standartized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrobial Agents and Chemotherapy. 2001; 45 (9): 2475–2479. DOI: 10.1128/aac.45.9.2475-2479.2001.

[17] Lisovskaya S.A., Glushko N.I., Khaldeeva E.V. et al. The effect of mycelial fungi in the adhesion of Candida albicans. Problemy meditsinskoy mikologii. 2010; 12 (1): 34–37. (In Russ.)

[18] Лисовская С.А., Глушко Н.И., Халдеева Е.В. и др. Влияние экстрактов мицелиальных грибов на адгезивные свойства Candida albicans. Пробл. мед. микол. 2010; 12 (1): 34–37.

[19] Naglik J.R., Challacomber S.J. Candida albicans secreted aspartil proteinases in virulence and pathogehesis. Miccrob. Mol. Biol. Rew. 2003; 67: 400–428. DOI: 10.1128/MMBR.67.3.400-428.2003. DOI: 10.17816/KMJ2020-342

[20] Naglik J.R., Challacomber S.J. Candida albicans secreted aspartil proteinases in virulence and pathogehesis. Miccrob. Mol. Biol. Rew. 2003; 67: 400–428. DOI: 10.1128/MMBR.67.3.400-428.2003.DOI: 10.17816/KMJ2020-342

RIGHTS & PERMISSIONS

Lisovskaya S.A., Valieva R.I., Sharifullina A.A., Fayzullina E.V., Khismatullina I.M., Khaldeeva E.V., Isaeva G.S.